(NASDAQ: ALIM) Alimera Sciences's forecast annual revenue growth rate of 16.57% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.56%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.11%.
Alimera Sciences's revenue in 2024 is $90,219,000.On average, 1 Wall Street analysts forecast ALIM's revenue for 2024 to be $5,509,699,912, with the lowest ALIM revenue forecast at $5,509,699,912, and the highest ALIM revenue forecast at $5,509,699,912.
In 2025, ALIM is forecast to generate $6,627,146,895 in revenue, with the lowest revenue forecast at $6,627,146,895 and the highest revenue forecast at $6,627,146,895.